AHA Coding Clinic® for HCPCS - 2023 Quarter 1; For Your Information
Updated Emergency Use Authorizations for COVID-19 vaccines
The U.S. Food and Drug Administration (FDA) has authorized amended versions of its emergency use authorizations (EUA) for the administration of COVID-19 vaccines for the prevention of COVID-19 infection. Effective October 19, 2022, the FDA revised the EUA for the adjuvanted Novavax COVID-19 vaccine. The EUA for Novavax previously included a two-dose primary vaccine series for persons aged 12 and older. Now, the revised EUA authorizes a first booster dose for patients 18 years and older, that are at least 6 months out from completion of a primary vaccination series with an authorized or approved COVID-19 vaccine, for...
Subscribe or sign in to view the full article.
Article Overview
This article covers an FDA update to emergency use authorizations for COVID-19 vaccines, with emphasis on changes affecting the Novavax vaccine and associated CPT reporting. It is relevant to coders, billers, and compliance staff who need to track vaccine authorization updates and the related billing codes for vaccine product and administration. The content presents the regulatory context and a concise code table showing the applicable reporting categories.
Why This Topic Matters
COVID-19 vaccine authorizations and billing guidance can change over time, affecting how services are documented and reported. Staying current helps support accurate claim submission and compliance with the latest FDA-related vaccine updates.
Article Sections
-
FDA update on COVID-19 vaccine emergency use authorizations
Overview of the FDA’s amended authorization status for COVID-19 vaccines and the general context for the update. The section focuses on the regulatory change and the population addressed by the revised authorization.
-
Emergency Use Authorizations for COVID-19 vaccines
A concise reporting table linking vaccine product information with administration reporting categories. The section presents the coverage by patient age, manufacturer, and CPT billing categories.
What You Will Learn
- What the article says about updated FDA authorization status for COVID-19 vaccines
- How the Novavax COVID-19 vaccine is addressed in the update
- Which billing categories are associated with the vaccine product and administration
- How the article frames the relevance of the authorization change for reporting
Who Should Read This
- Medical coders
- Medical billers
- Compliance staff
- Revenue cycle professionals
- Healthcare administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com